Yes, reduce the fenofibrate dose to 54 mg daily
With a GFR of 57 mL/min/1.73 m², you should reduce the fenofibrate dose from 145 mg to 54 mg daily. This patient falls into the mild-to-moderate renal impairment category (eGFR 30-59 mL/min/1.73 m²), which requires mandatory dose reduction according to both ACC/AHA and FDA guidelines.
Guideline-Based Dosing Requirements
The 2013 ACC/AHA guideline provides explicit dosing instructions: "If eGFR is between 30 and 59 mL/min per 1.73 m², the dose of fenofibrate should not exceed 54 mg/day" 1. This is a Class I recommendation with Level of Evidence B, meaning it's strongly recommended based on moderate-quality evidence.
The FDA drug label reinforces this, stating that dose reduction is required in patients with mild to moderate renal impairment (eGFR 30-59 mL/min/1.73 m²) 2. The label specifically instructs to "initiate therapy at 54 mg daily and assess the effects on kidney function and lipid concentrations" in this population 3.
Why This Matters
Fenofibrate undergoes primarily renal excretion, and pharmacokinetic studies demonstrate that patients with mild-to-moderate renal impairment experience:
- Similar drug exposure but increased half-life of fenofibric acid 2
- Risk of drug accumulation with standard dosing
- A 2.7-fold increase in exposure occurs only with severe impairment (eGFR <30), but dose adjustment is still needed at eGFR 30-59
Monitoring Requirements
After dose reduction to 54 mg daily:
- Recheck renal function within 3 months, then every 6 months 1
- Monitor both serum creatinine and eGFR
- Expect a reversible increase in serum creatinine of approximately 0.13 mg/dL (12 µmol/L) - this is a known pharmacologic effect, not necessarily nephrotoxicity 4
- Discontinue fenofibrate if eGFR persistently drops below 30 mL/min/1.73 m² 1
Common Pitfall to Avoid
Do not continue 145 mg dosing based on the assumption that a GFR of 57 is "close enough" to 60. The evidence shows that even mild renal impairment (eGFR 45-59) increases the risk of fenofibrate-associated nephrotoxicity, particularly when combined with other medications affecting renal hemodynamics like ACE inhibitors or ARBs 5. The 27% incidence of creatinine elevation ≥0.3 mg/dL within 6 months in one observational study emphasizes the importance of proper dosing 5.
Additional Considerations
If this patient is also taking a statin, be aware that fenofibrate can be used concomitantly (unlike gemfibrozil), but the combination increases muscle toxicity risk 1. The reduced dose of 54 mg may actually provide a better safety profile while maintaining efficacy for triglyceride lowering in the setting of CKD 6.